Please provide your email address to receive an email when new articles are posted on . The newly presented data is from the two STOP-HS trials, both of which met their primary endpoints. Povorcitinib ...

As they gain data maturity, state and local agencies are increasingly putting their information to work. In Washington, D.C., a real-time information dashboard helps first responders manage blood used ...

Venetoclax-obinutuzumab therapy shows sustained PFS and OS benefits over chemoimmunotherapy in untreated CLL patients with coexisting conditions. The CLL14 trial's 6-year follow-up confirms >50% of ...

MANCHESTER, England — Febuxostat (Uloric) did not appear to increase the risk for major adverse cardiovascular (CV) events (MACEs) when compared with no urate-lowering therapy (ULT) in people with ...